Stereo develops multi-specific immunotherapies that target peptide‑MHC (pMHC) complexes uniquely expressed on tumor cells, enabling precise T‑cell engagement while minimizing off‑target effects.
Funding
Funding not disclosed
Founders
Product
Problem
Solid tumors often exhibit heterogeneous expression of antigens, limiting the effectiveness of single-target immunotherapies and leaving many patients without viable treatment options. Conventional T‑cell engagers can also suffer from narrow therapeutic windows and off‑target toxicity when targeting broadly expressed proteins.
Solution
Stereo Bio creates multi‑specific immunotherapies that engage T cells through peptide‑MHC (pMHC) complexes uniquely presented on tumor cells. Their proprietary Broadcast platform identifies optimal pairs of pMHC targets, engineers small soluble T‑cell receptor subunits called Trackers, and formats them into drug‑like molecules with antibody‑like developability. By combining multiple pMHC targets, the approach broadens tumor coverage, addresses heterogeneity, and aims to improve safety by limiting activity to cells displaying the specific peptide‑MHC signatures. The platform is applied to solid‑tumor programs and is being extended to other oncology and autoimmune indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies for solid tumors and other diseases where target heterogeneity and specificity are critical challenges.
Features
- Broadcast platform that computationally selects high‑impact pMHC target pairs for multi‑specific design
- Trackers: engineered soluble TCR subunits that bind pMHC with natural specificity and drive T‑cell activation
- Multi‑specific formats optimized for drug‑like pharmacokinetics and manufacturability, resembling antibody properties
- Ability to address tumor heterogeneity by targeting multiple pMHC complexes simultaneously
- Extension of the technology to both oncology and autoimmune disease programs